anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a preparation method for a soaking-free silkworm cocoon composition. The method comprises the following steps that 1, folium mori silkworms are bred to the last phase of the period of 5 instar; 2, healthy matured silkworms are selected and are made to mount a cocooning frame through disposable squares; 3, one ends of silkworm cocoons obtained after five days of cocooning frame mounting in the step 2 are cut open, silkworm chrysalis is taken out, and the silkworm cocoons are set aside; 4, the silkworm cocoons in the step 3 are placed in a certain amount of a soaking solution of mulberry leaves to be boiled for 40 seconds to 3 minutes, and then are cooled for standby application. The soaking-free silkworm cocoon composition is convenient to use, soaking and other procedures are omitted, and the soaking-free silkworm cocoon composition can be unpackaged to be directly used. The soaking-free silkworm cocoon composition is processed through high-temperature sterilization and is safe and free of pollution. The soaking-free silkworm cocoon composition is soft and comfortable to use, and the skin cannot be damaged. The soaking-free silkworm cocoon composition contains much dissolved sericin which can be conveniently absorbed by the skin, and the whitening and moisture conservation effects are remarkable. The soaking-free silkworm cocoon composition has the effect of sterilizing and disinfecting the surface of the skin.
Patients will start nighttime cycled enteral feeds first for 12 hours. Following a 24-hour washout period, patients will then start daytime cycled enteral feeds for 12 hours.
PURPOSE:To obtain sodium bicarbonate particles, having treated surfaces and capable of forming tablet or granule, etc., and simultaneously providing formed formulations excellent in stability without using other binders by coating the surfaces of the sodium bicarbonate particles with Na2CO3 or a double salt thereof. CONSTITUTION:About >=50% surfaces of sodium bicarbonate particles having >=30mum average particle diameter are normally coated with Na2CO3 or a double salt thereof. In this case, the thickness of the Na2CO3 on the surfaces of the sodium bicarbonate particles is especially preferably 0.1 to 5mum. The surfaces of the sodium bicarbonate particles are coated by, e.g. heating the sodium bicarbonate particles at >=70 deg.C. For example, the surfaces of the sodium bicarbonate particles having 200mum average particle diameter may be converted into the sodium carbonate having about 1mum thickness by heating the surfaces at about 100 deg.C temperature for 30min. The resultant sodium bicarbonate particles with the treated surfaces have excellent binding force and the resultant formed formulation is simultaneously excellent in preservation stability.
The investigators will examine and observe the patient's stay in the PACU and utilize the pulse oximetry software and data to analyze the ability to evaluate the difference in patient oxygenation levels and supplemental oxygen use with automated verbal prompted monitoring versus a standard care control group. As well as determine if automated verbal prompted monitoring leads to less monitor alarms and subsequent improvement of subjective alarm fatigue and patient satisfaction with their care versus standard care.

The pulse oximeter will have a finger probe that will be attached to the patient's middle finger to read the patient's SpO2 levels. Each time the participant's pulse oximetry value declines to 93% or less, an automated verbal prompt, created via the software, will generate as a soft prompt. This will be followed up by a hard prompt if no improvement is seen in their oxygenation level after a period of time. A positive feedback elicitation will be given if the participant's saturation levels increase above 93%. This automated verbal prompt guidance will take place during the entirety of the investigational group's PACU stay.
Fentanyl is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4); therefore potential interactions may occur when ABSTRAL is given concurrently with agents that affect CYP3A4 activity. 

The concomitant use of ABSTRAL with CYP3A4 inhibitors (e.g., indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, telithromycin, aprepitant, diltiazem, erythromycin, fluconazole, grapefruit juice, verapamil, or cimetidine) may result in a potentially dangerous increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. Patients receiving ABSTRAL who begin therapy with, or increase the dose of, CYP3A4 inhibitors need to be carefully monitored for signs of opioid toxicity over an extended period of time. Increase dosage conservatively. 

The concomitant use of ABSTRAL with CYP3A4 inducers (e.g., barbiturates, carbamazepine, efavirenz, glucocorticoids, modafinil, nevirapine, oxcarbazepine, phenobarbital, phenytoin, pioglitazone, rifabutin, rifampin, St. John's wort, or troglitazone) may result in a decrease in fentanyl plasma concentrations, which could decrease the efficacy of ABSTRAL. 

Patients receiving ABSTRAL who stop therapy with, or decrease the dose of, CYP3A4 inducers need to be monitored for signs of increased ABSTRAL activity and the dose of ABSTRAL must be adjusted accordingly.
<P>PROBLEM TO BE SOLVED: To provide an aroma therapy, a health method for rubbing in skin, or a beauty method, for promoting the volatilization of a perfume, or an aroma produced from an aromatic plant in aroma therapy.  <P>SOLUTION: The volatilization of an aromatic oil is promoted to exhibit an effective aroma therapy effect for an ingredient composition. The volatilization of the aroma therapy aroma oil is preferably promoted by heating an inorganic porous, zeolite or diatomite container, a metal-processing container, a wood-processing container, an earthenware-processing container, a plastic-processing container, or a container comprising their combination. The volatilization of the aromatic oil extracted from a plant having an aroma therapy aromatic property is promoted with the processing container. The volatilization of the aroma is mass produced in a large amount with a relatively simple device without needing a high cost installation investment.  <P>COPYRIGHT: (C)2011,JPO&INPIT
A supplement that produces an increased feeling of alertness and reduces anxiety, or produce a feeling of calmness is described. In an exemplary embodiment, the supplement is all natural, and contains no or essentially no synthesized chemical. The supplement or the therapeutic ingredients, such as the ingredients within a capsule, may only contain plant matter. The plant matter may include plant roots and leaves, for example. The supplement and more specifically the active ingredient of the supplement may include,  piper methysticum  (kava kava root), brahmi ( bacopa ), ashwagandha (winter cherry). These three ingredients may be the primary active or therapeutic ingredients and may be provided in an effective amount to produce a feeling of alert calmness.
INTRODUCTION: Modular femoral components allow for patient-specific restoration of hip joint geometry and the reconstruction of extensive bone defects in revision total hip arthroplasty (THA); however, potential problems of modular implants such as taper corrosion and the risk of implant fracture continue to be of concern. The aim of the present study was to evaluate the clinical and radiological results of a cementless modular revision stem following revision surgery due to aseptic loosening and periprosthetic fracture and to assess patient-reported outcome measures (PROMs) in these patients at mid-term follow-up.
MATERIALS AND METHODS: In this study, a consecutive cohort of 75 patients who underwent primary revision THA at our institution using a modular cementless stem design (MRP-TITAN stem) was retrospectively evaluated at a mean follow-up of 7.7 years. Kaplan-Meier survivorship analyses were performed with revision of the femoral component for any reason as the end point. The Harris-Hip Score, the UCLA Activity Score, the Forgotten Joint Score and the SF-12 Score were used for clinical assessment. We used the Wilcoxon signed rank test to compare pre- and postoperative clinical scores.
RESULTS: Overall stem survival with the endpoint stem re-revision for any reason was 85.4% at a mean follow-up of 7.7 years (range 2.4-14 years). Stem survival was 89.5% in the aseptic loosening group and 78.3% in the periprosthetic fracture group with no statistically significant difference between both groups (p = 0.107). One patient had to be revised due to taper fracture. PROMs improved significantly up to the latest follow-up, and radiographic evaluation showed full osseointegration of all stems in this cohort.
CONCLUSIONS: Revision THA using a modular cementless titanium revision stem demonstrated adequate clinical and radiological results at mid- to long-term follow-up in this cohort. Cementless revision stems are a useful treatment option to restore the anatomy, especially in deformed hips and in complex revision hip arthroplasty. However, there are some significant disadvantages related to an increased risk of mechanical failure such as corrosion/fretting damage and implant fracture. Future high-quality prospective studies with longer follow-up are necessary to confirm the supposed advantages.
Patients who randomised to intervention group (Arm A) will receive HIFEM assisted (BTL EMsella) pelvic floor muscle training for total 6 sessions (2 session per week, 30 minutes per session with modulated intensity) plus standard of care. The intervention will be started within 2 weeks after Foley Catheter removed. Patients will attend follow up for training and at 1, 3 and 6 month post-operatively.
Infants with anophthalmia and microphthalmia (an/microphthalmia) have often other associated congenital anomalies. The reported frequency and the types of these associated anomalies vary between different studies. The purpose of this investigation was to assess the frequency and the types of associated anomalies among cases with an/microphthalmia in a geographically well defined population of northeastern France of 387,067 consecutive pregnancies from 1979 to 2007. Of the 98 infants with an/microphthalmia born during this period (prevalence at birth of 2.53 per 10,000), 88.8 % had associated anomalies. Cases with associated anomalies were divided into recognizable conditions (25 (25.5%) cases with chromosomal and 17 (17.3%) cases with non chromosomal conditions), and non recognizable conditions (45-45.9%- cases with multiple congenital anomalies -MCA). Trisomy 13 and trisomy 18 were the most frequent chromosomal abnormalities. Amniotic bands sequence, oculo-auriculo-vertebral spectrum, CHARGE syndrome and VACTERL association were most often present in recognizable non chromosomal conditions. Anomalies in the musculoskeletal, cardiovascular and central nervous systems were the most common other anomalies in cases with MCA and non recognizable conditions. However, given the limitation of the limited numbers of cases there should be urging caution in interpreting these results. In conclusion the frequency of associated anomalies in infants with anophthalmia and microphthalmia emphasizes the need for a thorough investigation of these cases. Routine screening for other anomalies especially musculoskeletal, cardiac and central nervous systems anomalies may need to be considered in infants with anophthalmia and microphthalmia, and referral of these cases for genetic counselling seems warranty.
In a pilot randomized controlled clinical trial, 18 stroke survivors more than 6 months after stroke onset, and have upper limb impairment will be enrolled. Participants will be randomized to receive a form of non-invasive brain stimulation called repetitive transcranial magnetic stimulation or rTMS or sham rTMS. Real or sham rTMS will be delivered over an area in the brain called the higher motor cortices within the stroke-unaffected hemisphere, cHMC for short. This area (cHMC) is important for using both arms and hands together, or bimanual motor function. Real or sham cHMC rTMS will be given prior to upper limb therapy twice a week for 6 weeks in the lab. The investigators will measure bimanual motor function and control twice at the beginning, once after the 6-week treatment and once at 1-month after treatment. The investigators will also test possible mechanisms related to the treatment using brain functional MRI and TMS twice at the beginning and once after 6-week treatment.
Tenofovir disoproxil fumarate (a prodrug of tenofovir) is a fumaric acid salt of bisisopropoxycarbonyloxymethyl ester derivative of tenofovir. In vivo tenofovir disoproxil fumarate is converted to tenofovir, an acyclic nucleoside phosphonate (nucleotide) analog of adenosine 5'-monophosphate. 

Tenofovir exhibits activity against HIV-1 reverse transcriptase. 

The chemical name of tenofovir disoproxil fumarate is 9-[(R)-2-[[bis[[(isopropoxycarbonyl)oxy]methoxy]phosphinyl]methoxy]propyl]adenine fumarate (1:1). It has a molecular formula of C19H30N5O10P • C4H4O4 and a molecular weight of 635.52. It has the following structural formula:

Tenofovir disoproxil fumarate is a white to off-white crystalline powder with a solubility of 13.4 mg/mL in distilled water at 25 °C. It has an octanol/phosphate buffer (pH 6.5) partition coefficient (log p) of 1.25 at 25 °C.

Tenofovir disoproxil fumarate is available as tablets.

Tenofovir disoproxil fumarate tablets are for oral administration in strength of 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. Each tablet contains the following inactive ingredients: croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and pregelatinized starch. The tablets are coated with Opadry White Y-1-7000, which contains Hypromellose, Titanium dioxide USP & Polyethylene glycol 400 (Macrogol) USP.

In this insert, all dosages are expressed in terms of tenofovir disoproxil fumarate except where otherwise noted.
HIV infected children and adolescents on anti-HIV treatment regimens have traditionally had more difficulty with non-adherence and drug resistance than adults, often resulting in virologic failure. Additionally, HIV infected children with extensive exposure to antiretrovirals (ARVs) are likely to have fewer therapeutic options for salvage therapy, and their physicians find it difficult to choose regimens that will keep the HIV infection under control. This study will compare the efficacy of three 4-drug ARV salvage regimens in treatment-experienced, HIV infected children and adolescents who have experienced virologic failure.

This study will last at least 96 weeks. Participants will be randomly assigned to one of three groups. Group 1A will receive a dual-PI based regimen of lopinavir/ritonavir (LPV/r), saquinavir (SQV), and the NRTIs emtricitabine (FTC) and abacavir sulfate (ABC). Group 1B will receive a dual-PI based regimen of LPV/r, SQV, FTC, and tenofovir disoproxil fumarate (TDF). Group 2 will receive an NRTI-only regimen of ABC, lamivudine, zidovudine, and TDF.

There will be 11 study visits during Step I of this study. Medical history, a physical exam, and blood collection will occur at all visits. Dual-energy x-ray absorptiometry (DEXA) scans will occur at study entry and at Weeks 24, 48, 72, and 96. Urine collection will occur at most visits; participants will also take part in adherence modules at most visits. Participants will be asked to complete a pill count form at Weeks 4 and 24. Additionally, some study participants will be asked to participate in an intensive pharmacokinetics study at Week 4.
Based on clinical practice experience in patients treated with Acyclovir Ointment 5% in the US, spontaneously reported adverse events are uncommon. Data are insufficient to support an estimate of their incidence or to establish causation. These events may also occur as part of the underlying disease process. Voluntary reports of adverse events that have been received since market introduction include:

General:Edema and/or pain at the application site. 

Skin:Pruritus, rash. 

To report SUSPECTED ADVERSE REACTIONS, contact Taro Pharmaceuticals U.S.A., Inc. at 1-866-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Introduction The most common goal of functional endoscopic sinus surgery (FESS) is to improve quality of life (QOL). Changes in QOL or treatment effect can be measured using validated instruments completed by patients. One's perception of QOL is often a dynamic experience and has been shown to be affected by current medical and emotional state. This phenomenon is known as response shift in QOL research and can be measured by using the Then-test. This test asks patients to complete the same pre-operative survey of their symptoms during the post-operative period. This test aims to characterize any changes in one's perception of the pre-operative condition. The aim of this study is to assess the significance of response shift on sinus surgery outcomes measured using the sino-nasal outcome test (SNOT-20), a validated questionnaire used to assess the severity of symptoms related to chronic rhinosinusitis.

Methods This was a prospective cohort study approved by the University of Washington IRB. We approached all patients who underwent FESS for chronic rhinosinusitis from 2010-2012 who completed a pre-operative SNOT-20. We aimed to recruit 30 patients. Patients were mailed 2 SNOT-20 forms and a transition QOL scale at least 6 months after surgery. Patients were instructed to complete 1 SNOT-20 according to their pre-operative symptoms (then-test) and the other according to their post-operative symptoms. The difference between the pre- and post-operative SNOT-20 was calculated which represents the treatment effect, while the difference between the pre-operative SNOT-20 and then-test represents the response shift. A student t-test was used to compare these differences.

Results A total of 32 complete responses were obtained. Using a 0 to 5 SNOT-20 scale, the average treatment effect was -0.96 (p=0.00) and the average response shift was +0.42 (p=0.01). The negative treatment effect signifies an improvement in QOL. The positive response shift signifies that on average, patients thought they were even more symptomatic prior to surgery. The actual treatment effect is the sum of treatment effect and response shift which was -1.38.

Discussion Response shift exists and can be quantified in FESS outcomes. The actual treatment effect was more profound when taking into account response shift, therefore future studies should account for this often unmeasured, potential change in QOL.
The present invention relates to sleepiness assessment. In order to provide a more accurate measure to predict OSA severity, an apparatus is provided for sleepiness assessment. The apparatus comprises an input unit, a processing unit, and an output unit. The input unit is configured to receive data indicative of an activity currently performed by a user. The processing unit is configured to determine, based on the activity currently performed by the user, a current situation the user is engaging in. The processing unit is configured to determine whether the current situation matches one of a plurality of pre-determined situations used for situational sleepiness assessment. In response to the determination that the current situation matches one of the plurality of predetermined situations, the processing unit is configured to send a notification to the user for a self-report of a user's current subjective sleepiness level and/or obtain a user's current objective sleepiness level from sensor data. The processing unit is further configured to generate, based on the determined situation and the user's current subjective and/or objective sleepiness level, a situational sleepiness profile indicative of a sleep disturbance on daytime sleepiness in specific situations. The output unit is configured to provide the generated situational sleepiness profile, which is preferably useable to support sleep apnea diagnostics.
Neuroscience based proprioceptive training using laser pointer A pre-created wallpaper indicating various directions is fixed on the wall 90 cm away from the patient (at the level of the patient's knee when the patient is standing upright). Then, the laser pointer (producted by NMC training system) will fixed to the patient's knee with the help of a velcro so as not to interfere with the patient's knee movement. At the beginning of the exercise, the patient is asked to move the light on the laser pointer to the midpoint of the wallpaper. The patient is then asked to follow the instructions on the wallpaper by moving the knee in flexion-extension, medio-lateral directions. These instructions are continued throughout the exercise in different directions. Meanwhile, the patient is asked to perform mild cognitive tasks such as counting numbers, names of people starting with any letter, city names or animal names. The training continued for approximately 20 minutes.
BACKGROUND & AIMS: Osteosarcopenia is a recently recognized geriatric syndrome. The association between osteosarcopenia and mortality risk is still largely underexplored. In this systematic review with meta-analysis of prospective cohort studies, we aimed to explore whether osteosarcopenia could be associated with a higher mortality risk.
METHODS: Several databases were searched from the inception to 16th February 2024 for prospective cohort studies dealing with osteosarcopenia and mortality. We calculated the mortality risk in osteosarcopenia vs. controls using the most adjusted estimate available and summarized the data as risk ratios (RRs) with their 95% confidence intervals (CIs). A random-effect model was considered for all analyses.
RESULTS: Among 231 studies initially considered, nine articles were included after exclusions for a total of 14,429 participants (mean age: 70 years; 64.5% females). The weighted prevalence of osteosarcopenia was 12.72%. Over a mean follow-up of 6.6 years and after adjusting for a mean of four covariates, osteosarcopenia was associated with approximately 53% increased risk of mortality (RR: 1.53; 95% CI: 1.28-1.78). After accounting for publication bias, the re-calculated RR was 1.48 (95%CI: 1.23-1.72). The quality of the studies was generally good, as determined by the Newcastle Ottawa Scale.
CONCLUSIONS: Osteosarcopenia was significantly linked with an increased risk of mortality in older people, indicating the need to consider the presence of osteoporosis in patients with sarcopenia, and vice versa, since the combination of these two conditions typical of older people may lead to further complications, such as mortality.
The invention relates to the design and synthesis of prodrugs of positively charged retinoids and retinoid-like compounds having the general formula (31) 'Structure 31'. The compounds can be obtained by reacting retinoic acid and related compounds with suitable alcohols, thiols, or amines via coupling reagents. Experimental results indicate that more than 90% of the prodrug can change back to the parent drug within minutes. In therapy, these prodrugs can be administered transdermally for any kind of treatment, avoiding most of the side effects of retinoids and retinoid-like compounds. The controlled-release transdermal drug delivery system of the prodrug can stabilize the concentration of the vitamin A acids and the retinoid acid compounds in blood at the optimal treatment concentration, improve the curative effect and reduce the side effects of the vitamin A acids and the retinoid acid compounds. Another great benefit of transdermal administration of these prodrugs is that it is more convenient to use, especially for children.